Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response

Journal of Viral Hepatitis

Volumn 12, Issue 5, 2005, Pages 473-480

  Carlsson, T ^a   Reichard, O ^a   Norkrans, G ^b   Blackberg J ^c   Sangfelt, P ^d   Wallmark, E ^c   Weiland, Ola ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Hepatitis C virus RNA; Pegylated interferon 2a; Ribavirin; Sustained virological response

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ACCURACY; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KINETICS; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; RNA ISOLATION; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; VALIDATION PROCESS; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIREMIA;

EID: 24044531933     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00621.x     Document Type: Article

References (28)

1. Tine F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol 1991; 13: 192-199.
2. Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. J Viral Hepat 2001; 8: 48-62.
3. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
4. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
5. Hadziyannis SJ, Sette HJ, Morgan TR et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
6. Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996; 23: 366-371.
7. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-107.
8. Neumann AU, Lam NP, Dahari H et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 28-35.
9. Zeuzem S, Hermann E, Lee JL et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alfa-2a. Gastroenterology 2001; 120: 1438-1447.
10. Carlsson T, Weiland O, Reichard O. Viral kinetics and treatment response in patients with hepatitis C during induction and standard interferon therapy in combination with ribavirin. Scand J Gastroenterol 2002; 37: 1228-1234.
11. Zeuzem S, Schmidt JM, Lee J-H, von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998; 28: 245-252.
12. Zeuzem S, Lee J-H, Franke A et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998; 27: 1149-1156.
13. Davis G, Wong JB, McHutchison JG, Manns M, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-652.
14. Bjoro K, Bell H, Hellum K et al. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study. Scand J Gastroenterol 2002; 37: 226-232.
15. Carithers RI Jr, Zeuzem S, Mann MP et al. Multicenter, randomized, controlled trial comparing high dose daily induction interferon plus ribavirin versus standard interferon alfa-2b plus ribavirin. Hepatology 2000; 32: 317A.
16. Ferenci P, Brunner H, Nachbaur K et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001; 34: 1006-1011.
17. Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology 2000; 32: 654-659.
18. Doglio A, Laffont C, Caroli-Bose FX, Rochet P, Lefebre J. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant. J Clin Microbiol 1999; 37: 1567-1569.
19. Stuyver L, Wyseur A, Arnhem VW, Hernandez F, Maertens G. Second- generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996; 34: 2259-2266.
20. Yun ZB, Lara C, Johansson B, Lorenzana de Rivera I, Sönnerborg A. Discrepancy hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences. J Med Virol 1996; 49: 155-160.
21. Batts KP, Ludwig J. Chronic hepatitis. Am J Surg Pathol 1995; 19: 1409-1417.
22. Schvarcz R, Glaumann H, Reichard O, Weiland O. Histological and virological long-term outcome in patients treated with interferon alfa-2b and ribavirin for chronic hepatitis C. J Viral Hepat 1999; 6: 237-242.
23. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002 - June 10-12, 2002. Hepatology 2002; 36: S3-S20.
24. Jessner W, Gschwantler M, Steindl-Munda P et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001; 358: 1241-1242.
25. Jessner W, Stauber R, Hackl F et al. Early viral kinetics on treatment with pegylated interferon-α-2a in chronic hepatitis C virus genotype 1 infection. J Viral Hepat 2003; 10: 37-42.
26. Buti M, Sanchez-Avila F, Lurie Y et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002; 35: 930-936.
27. Keating GM, Curran MP. Peginterferon-α-2a (40 kD) plus ribavirin. Drugs 2003; 63: 701-730.
28. Lee SS, Heathcote EJ, Reddy KR et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40 KD). J Hepatol 2002; 37: 500-506.